11:50:51 EDT Fri 12 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:MNKD - MANNKIND CORPORATION - http://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q2.25.65·5.661.75.66+0.050.9678.53,7002,3045.68  5.765  5.625.75  3.1711:32:41Jun 2215 min RT 2¢

Recent Trades - Last 10 of 2304
Time ETExPriceChangeVolume
11:32:41Q5.660.05100
11:32:39Q5.6550.045100
11:32:19Q5.660.05200
11:32:17Q5.660.051
11:32:10Q5.65450.044518
11:32:10Q5.6550.0451
11:31:57Q5.6550.0452
11:31:47Q5.6550.0451
11:31:30Q5.6550.0451
11:31:19Q5.65110.041117

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-22 08:00U:MNKDNews ReleaseINHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions
2024-06-05 06:45U:MNKDNews ReleaseInhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
2024-05-29 08:45U:MNKDNews ReleasePulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
2024-05-29 08:45U:MNKDNews ReleaseMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
2024-05-08 16:19U:MNKDNews ReleaseMannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
2024-05-06 06:05U:MNKDNews ReleaseMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
2024-05-01 16:00U:MNKDNews ReleaseMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
2024-04-30 06:05U:MNKDNews ReleaseMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
2024-04-29 06:05U:MNKDNews ReleaseMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
2024-04-03 06:00U:MNKDNews ReleaseMannKind Repays Certain Debt Obligations
2024-03-26 16:05U:MNKDNews ReleaseMannKind Announces CFO Transition
2024-03-11 06:05U:MNKDNews ReleaseINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza(TM) Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
2024-03-05 06:05U:MNKDNews ReleaseMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
2024-03-04 13:01U:MNKDNews ReleaseMannKind Corporation Announces Participation at Upcoming Conferences
2024-02-27 16:00U:MNKDNews ReleaseMannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
2024-02-20 06:00U:MNKDNews ReleaseMannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
2024-02-15 06:05U:MNKDNews ReleaseMannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza ‚ ®
2024-01-02 06:05U:MNKDNews ReleaseMannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
2023-12-28 06:00U:MNKDNews ReleaseMannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 16:00U:MNKDNews ReleaseMannKind Corporation Reports 2023 Third Quarter Financial Results